Genomic testing gets a booster shot

Demand surges beyond metro cities

- ANJALI SINGH

Demand for genomic testing in India has surged significantly over the past 2-3 years, fueled by growing clinical awareness, rapid technological advancements, and the rising adoption of personalized medicine.

From being a niche service in Tier-I cities, genomic diagnostics is now expanding into Tier II and III cities. It is thus reshaping the landscape of preventive and precision healthcare.

The Indian genomic diagnostics market was valued at $550 million in 2024. It is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates.

Key drivers include wider physician adoption, declining test prices, improved accessibility, and a shift in consumer behaviour towards proactive and personalized healthcare.

Diagnostics majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging & Labs, and Redcliffe Labs reported double-digit growth in the segment.

While metros like Mumbai, Bengaluru, and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi, and Surat are driving demand beyond urban hubs.